Loss of function in the p53 tumor suppressor gene due to mutation occurs early in astrocytoma tumorigenesis in about 30-40% of cases. This is believed to confer a growth advantage to the cells, allowing them to clonally expand due to loss of the p53-controlled G 1 checkpoint and apoptosis. Genetic instability due to the impaired ability of p53 to mediate DNA damage repair further facilitates the acquisition of new genetic abnormalities, leading to malignant progression of an astrocytoma into anaplastic astrocytoma. This is re ected by a high rate of p53 mutation (60-70%) in anaplastic astrocytomas. The cell cycle control gets further compromised in astrocytoma by alterations in one of the G 1 /S transition control genes, either loss of the p16/CDKN2 or RB genes or ampli cation of the cyclin D gene. The nal progression process leading to glioblastoma multiforme seems to need additional genetic abnormalities in the long arm of chromosome 10; one of which is deletion and/or functional loss of the PTEN/MMAC1 gene. Glioblastomas also occur as primary (de novo) lesions in patients of older age, without p53 gene loss but with ampli cation of the epidermal growth factor receptor (EGFR) gene. In contrast to the secondary glioblastomas that evolve from astrocytoma cells with p53 mutations in younger patients, primary glioblastomas seem to be resistant to radiation therapy and thus show a poorer prognosis. The evaluation and design of therapeutic modalities aimed at preventing malignant progression of astrocytomas and glioblastomas should now be based on stratifying patients with astrocytic tumors according to their genetic diagnosis. Neuro-Oncology 1, 124-137, 1999 (Posted to Neuro-Oncology [serial online], Doc. 98-17, April 30, 1999 
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In the CNS, p53 mutation is frequently found in astrocytic tumors and, to a lesser degree, in primary malignant lymphomas. In this article, we discuss the roles of p53 mutation in the tumorigenesis and malignant progression of astrocytic tumors and relate it to other genetic alterations occurring in these tumors.
Evidence for the Involvement of p53 in Astrocytoma Tumorigenesis
There have been several lines of evidence showing that loss of p53 function plays a de nite role in astrocytoma tumorigenesis. p53 (-/-) astrocytes derived from p53 knockout mice show an increased growth rate and become spontaneously immortalized in successive cultures. On the other hand, astrocytes with hemizygous p53 alleles appear normal until a clone that loses the remaining wild-type allele emerges in the population (Bögler et al., 1995) . These observations show that loss of p53 function confers an in vitro growth advantage on astrocytes. After several passages, p53 (-/-) astrocytes become aneuploid and transformed, as evidenced by their growth in soft agar, serum-free medium or in nude mice; whereas cells with wild-type p53 function never transform after in vitro passaging. This suggests that genetic instability due to p53 loss facilitates the occurrence of other genetic abnormalities necessary for transformation (Bögler et al., 1995; Yahanda et al., 1995) . Li-Fraumeni syndrome, caused by a germline mutation in one p53 allele, serves as a natural experiment in humans. This syndrome is characterized by the frequent occurrence of malignant tumors early in life (Malkin et al., 1990) , including astrocytomas. Patients with multifocal gliomas are also shown to harbor a high frequency of germline p53 alterations (Kyritsis et al., 1994) . These data support the concept that loss of p53 function is an early event in astrocytoma tumorigenesis.
Another piece of evidence is that the neoplastic phenotype of astrocytic tumor cells can be reverted by restoration of p53 function. Transduction of wild-type p53 genes in p53-de cient glioblastoma cells results in growth arrest and/or apoptosis (Gomez-Manzano et al., 1997; Mercer et al., 1990; Van Meir et al., 1995) .
Prevalence of p53 Mutations and 17p Loss of Heterozygosity in Astrocytic and Nonastrocytic Neoplasms
We have applied a novel p53 functional assay in yeast to analyze p53 status in astrocytic and nonastrocytic tumors (Flaman et al., 1995) . This assay can accurately detect inactivating p53 mutations as red yeast colonies, does not detect polymorphisms, and in our hands is more reliable than previous conventional methods ( Kashiwazaki et al., 1997; Waridel et al., 1997) . This assay tests the transcriptional competence of p53 complexes synthesized on p53 cDNA generated by reverse transcriptase-polymerase chain reaction from tumor. p53 gene mutations were exclusively found in astrocytic neoplasms and primary malignant lymphomas . The results for astrocytic tumors are shown in Table 1 and compared with the previously documented p53 mutations and loss of heterozygosity data on chromosome 17p. With this assay, we did not detect any inactivating mutations in 16 cases of World Health Organization grade I pilocytic astrocytoma (Ishii et al., 1998) . Together with the previous DNA structure-based analyses that reported a rare occurrence of p53 mutations and the fact that pilocytic astrocytomas only rarely undergo progression to a higher grade , we
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c Ishii et al., 1998. may conclude that p53 mutation is not relevant to tumorigenesis of pilocytic astrocytomas, making it an entity genetically distinct from the grade II-IV spectrum. In contrast, p53 mutations were detected in considerable fractions of higher-grade astrocytic tumors, indicating that loss of p53 function plays an important role in tumorigenesis of subsets of these tumors. It is particularly interesting that anaplastic astrocytomas showed the highest prevalence (67%) of p53 mutation . This is also apparent in the previously documented mutations in anaplastic astrocytomas (30% ;  Table 1 ). This counterintuitive phenomenon that the less malignant anaplastic astrocytomas show a higher mutation rate than more malignant glioblastomas is explainable if we consider dual pathways of malignant progression to glioblastoma: one pathway where low-grade astrocytoma progresses to glioblastoma by expansion of mutated p53 cells and another where glioblastoma occurs de novo without p53 mutations. Table 2 shows a collective summary of reported p53 mutations in nonastrocytic glial tumors. Ependymomas and primitive neuroectodermal tumors/medulloblastomas only rarely display p53 mutations, even though they often contain an astrocytic component Saylors et al., 1991) . Although pure oligodendrogliomas rarely harbor mutant p53 genes, one-third of the cases of mixed oligoastrocytoma show aberrant p53 genes (Maintz et al., 1997; Reifenberger et al., 1996) . It is interesting that the other two-thirds display allelic loss of chromosomes 1p and 19q, which is often seen in pure oligodendroglioma (Maintz et al., 1997) , suggesting that oligoastrocytoma might originate through a transformation in either the astrocytic lineage due to p53 mutations or the oligodendrocytic lineage without involvement of p53 mutation.
Consequences of p53 Functional Loss due to Mutation/Allelic Loss
Loss of G 1 Check Point and DNA Repair: Uninhibited Growth and Genetic Instability p53 arrests cells possessing DNA damage in the G 1 phase of the cell cycle and promotes the cellular mechanisms of DNA repair. These functions are accomplished by transcriptional activation of CDK 3 inhibitor p21/CDKN1, and a set of mismatch repair genes, such as human mutS homologue-2 (hMSH2) (Scherer et al., 1996) , growth arrest DNA damage inducible-45 (GADD45) (Carrier et al., 1994; Hollander et al., 1993) , and PCNA (proliferating-cell nuclear antigen; cofactor of DNA polymerase d and e) (Morris et al., 1996) . In addition, p53 controls centrosome formation in the M-phase (Fukasawa et al., 1996) . Loss of these p53 functions through mutation and allelic loss results in uninhibited cellular growth, genetic instability, and malignant transformation of the cells (Agapova et al., 1996; Liu et al., 1996) .
Loss of Apoptosis: Immortalization
p53 transactivates the gene encoding pro-apoptotic factor, Bax, which triggers apoptosis (Miyashita and Reed, 1995) and represses the transcription of the Bcl-2 gene whose product suppresses apoptosis (Miyashita et al., 1994) . Bcl-2 is present on the mitochondrial outer membrane and tethers CED-4/caspase 3 complexes, which are released in the presence of Bax by competitive binding to the binding-site of CED-4. Bax also creates "megapores" on the mitochondrial membranes by a notyet-de ned mechanism that leads to "permeability transition" of the membrane and release of apoptosis-inducing factors (AIF) such as cytochrome c (Kroemer, 1997; Reed, 1997) . The released caspase 3, also called CPP32, is further activated by caspase 1 (interleukin-1b converting enzyme; ICE), which in turn is activated by a cytochrome c-mediated process, cleaves PARP (poly(ADP) ribose polymerase), and thereby initiates an apoptotic cascade reaction (Kluck et al., 1997; . Caspase 3 also cleaves Bcl-2 into a Bax-like pro-apoptotic factor, enhancing the mitochondrial change ( Fig. 1.) (Cheng et al., 1997) .
The activation of p53, however, does not always induce this apoptotic process; there is a selection between G 1 arrest and apoptosis, depending on cell-type and condition (Polyak et al., 1996) . p21/CDKN1 and RB (retinoblastoma susceptibility) proteins have recently been considered to mediate the selection. For apoptosis, the Rb protein is dephosphorylated by a serine/threonine phosphatase and cleaved into two proteins, p48 and p68, by a caspase-like protease (Fattman et al., 1997; Fu et al., 1998) . p48 remains in the cytosol, while p68 moves into the nucleus where it abrogates transcriptional activity of E2F without binding to it. Since transcriptional repression mediates the apoptosis induced by E2F overexpression (Hsieh et al., 1997) , it is conceivable that the liberated E2F, which lacks transactivation competence but retains transcriptional repressive activity, grants permis-M. Nozaki et al.: p53 and other gene loss in astrocytomas
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A P R I L 1 9 9 9 126 Hsieh et al., 1994; Metzger et al., 1991; Nozaki et al., 1998; Ohgaki et al., 1991 PNET/medulloblastoma 5/81 6 Adesina et al. Badiali et al., 1993; Hsieh et al., 1994; Ohgaki et al., 1993; Reifenberger et al., 1996; Saylors et al., 1991; Tsumanuma et al., 1995; Wu et al., 1993 sion to proceed with apoptosis. By preventing cell cycle progression to the late G 1 phase, during which E2F is synthesized, p21 may prevent this permission of E2F ( Fig. 1 ) (Hsieh et al., 1997; Waldman et al., 1997) . Loss of p53 function results in lack of p53-dependent apoptosis, conferring resistance to DNA damaging agents. On the other hand, however, retention of wildtype p53 function does not warrant better sensitivity to DNA damaging agents in certain tumor cells (Kondo et al., 1996) , particularly in glioblastoma cells, as discussed later. Predominant induction of p21 compared with Bax, in fact makes G 1 arrest a preferred event over Rb cleavage and apoptosis in glioblastoma cells (Jung et al., 1995; Wagenknecht et al., 1997) .
Loss of Gene Regulatory Function and "Gain of Function"
Other genes that are transactivated by p53 include MDM2 (murine double-minute 2) (Barak et al., 1993) , EGFR (epidermal growth factor receptor) (Deb et al., 1994; Ludes Meyers et al., 1996) , TGF-a (transforming growth factor-a) (Shin et al., 1995) , DDR (discoidin domain receptor) , IGF-BP3 (insulin-like growth factor binding protein 3) (Buckbinder et al., 1995) , cyclin G (Okamoto and Beach, 1994) , and A28-RGS14 (G-protein regulator) (Buckbinder et al., 1997). In addition to its function as a speci c transcriptional activator, p53 is known to act as a transcriptional repressor for genes with TATA and CAAT boxes in their promoter sequence (Agoff et al., 1993; Mack et al., 1993; Ragimov et al., 1993) . The repressed genes include cyclin A (Desdouets et al., 1996) , IGFII , IGFI receptor (Werner et al., 1996) , VEGF (vascular endothelial growth factor) (Mukhopadhyay et al., 1995) , bFGF (basic broblast growth factor) (Ueba et al., 1994) , interleukin 6 (Margulies and Sehgal, 1993; Santhanam et al., 1991) , MDR1 (multiple drug resistance 1) (Zastawny et al., 1993) , MGMT (O 6 -methylguanine methyl transferase) (Harris et al., 1996) , iNOS (inducible nitric oxide synthase) (Forrester et al., 1996) , c-fos (Ginsberg et al., 1991) , c-jun (Kieser et al., 1994) , hsc70 (heat shock cognate protein 70) (Ginsberg et al., 1991) , and hsp70 (heat shock protein 70) (Agoff et al., 1993) . Thus, loss of p53 function may cause derepression (or release from repression) of these genes, leading to augmented expression of autocrine growth factors and their receptors, paracrine angiogenic cytokines, drug resistant genes, and growth-promoting oncogenes.
Furthermore, certain p53 mutants, such as 175H and 248Q, paradoxically up-regulate transcription of several genes, including IGFI receptor (Werner et al., 1996) , EGFR (Ludes Meyers et al., 1996) , VEGF (Kieser et al., 1994) , IL6 (Santhanam et al., 1991) , and MDR1 (Zastawny et al., 1993) . These effects could be explained by dominant negative action of mutant p53 on the repressive activity of wild-type p53 in heterozygous cells. However, when transfected into p53 null cells, mutants can confer dominant oncogenic properties, such as an increased tumorigenicity, suggesting a gain of function (Elledge and Lee, 1995).
p53 Mutation and Prognosis of Glioma Patients

Two Subsets of Glioblastoma Multiforme: Malignant Progression from Low-Grade Astrocytomas or De Novo Glioblastomas
It has recently been proposed that adult cerebral glioblastomas comprise at least two subsets that are clinically and genetically distinct. Type 1 denotes the secondary glioblastoma, which is considered to have undergone stepwise malignant progression from low-grade astrocytoma and is marked by loss of p53 function (Sidransky et al., 1992; Tada et al., 1996) . Type 2 represents the de novo or primary glioblastoma, which occurs without a preceding lesion, has intact p53 function, but shows ampli cation of the EGFR gene (Leenstra et al., 1994) . Table 3 shows characteristics of the two glioblastoma subsets drawn from recent literature. Clinically, type 1 affects relatively younger patients and shows somewhat longer survival, whereas type 2 occurs in elderly patients and is associated with shorter survival (Leenstra et al., 1994; von Deimling et al., 1993) . Using conventional techniques (i.e., SSCP) for detecting p53 mutations, the difference in survival between the two subsets has remained unclear, but using a yeast p53 functional assay, a signi cant difference in survival between groups of patients with or without the p53 gene mutation was found . Adult patients with cerebral glioblastoma survived 14.2 ± 1.7 months when p53 was wild-type and 29.7 ± 3.3 when p53 was mutated (P<0.0003). Surprisingly, the difference in survival times between the two groups appeared due mainly to a difference in the period of tumor growth control after radiation (regrowth-free period). Survival time after regrowth was independent of p53 status, suggesting that the difference in survival was related to the treatment rather than the intrinsic aggressiveness of the tumor . Because of the small number of tumors (36) analyzed in this study, it will be important to con rm them in a larger patient series. This observation contrasts with the well-accepted hypothesis that p53 inactivation is associated with decreased radiosensitivity due to abrogated p53-dependent apoptosis (Clarke et al., 1993; Lowe et al., 1993) . As mentioned before, however, when p21 is the predominant factor induced by p53 rather than the pro-apoptotic factors, the consequent G 1 arrest blocks the cell cycle progression necessary for p53-dependent apoptosis, resulting in a decreased sensitivity to DNA-damaging agents (Yount et al., 1996) . It is also possible that glioblastoma without p53 mutation harbors another genetic defect elsewhere that causes radioresistance. In glioblastoma cells with p53 mutations, radiation does not block cell cycle progression, thus allowing G 2 Mrelated p53-independent apoptosis to occur (Allday et al., 1995; Hsieh et al., 1997; Strasser et al., 1994) . Similar associations of p53 mutation with higher sensitivity to DNA-damaging agents have been reported in other types of cancers (Cote et al., 1997; Fan et al., 1995; Wahl et al., 1996) .
Malignant Progression from Low-Grade Astrocytoma
Although p53 inactivation plays an important role in astrocytoma progression, it is not the sole factor determining the progression, since almost all low-grade astrocytomas recur within 5-15 years after initial surgical M. Nozaki et al.: p53 and other gene loss in astrocytomas
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http://neuro-oncology.oxfordjournals.org/ removal, and 80% of these are associated with malignant progression (Kraus et al., 1994; Muller et al., 1977) . Loss of other tumor suppressor genes, such as PTEN and RB, appear essential for malignant progression of astrocytomas in the absence of p53 mutation. Van Meyel et al. (1994) observed that progression of a grade 2 astrocytoma into an anaplastic astrocytoma occurs frequently with p53 mutation, but direct progression into a glioblastoma does not, indicating another pathway of malignant progression not requiring p53 mutation (van Meyel et al., 1994) . MDM2 gene ampli cation and overexpression are seen in about 10% of high-grade astrocytomas but in none of grade II astrocytomas (Costanzi-Strauss et al., 1998) . The Mdm2 protein opposes the functions of p53 directly by inhibiting its transcriptional activity and promoting its degradation (Chen et al., 1996; Haupt et al., 1996 Haupt et al., , 1997 Momand et al., 1992; and indirectly by interacting with E2F1 and Rb family proteins, p107 and Rb1 (Dubs-Poterszman et al., 1995; Haupt et al., 1997; Kubbutat et al., 1997; Martin et al., 1995; Xiao et al., 1995) . MDM2 amplication is thus considered to replace p53 inactivation in the astrocytic tumors without p53 mutation. Moreover, we have recently shown that the presence of short alternative transcript forms of MDM2 is highly correlated with malignancy of astrocytic tumors . Since the short alternative transcript products do not contain the p53 binding domain, they may carry oncogenic functions rather than interfering with the p53 protein.
Abnormality of Other Genes as Alternatives to the p53 Inactivation Pathway
p53 inactivation causes a set of tumor phenotypes essential for glioma development, including uninhibited growth, genetic instability, suppressed apoptotic cell death (immortalization), and altered gene expression that supports tumor growth. This immediately raises the question of what gene abnormalities would replace p53 mutations in wild-type p53 gliomas, which are histologically indistinguishable from mutant p53-harboring glioblastomas (Table 4) .
EGFR Ampli cation and PTEN/MMAC1 Loss
Ampli cation of the EGFR gene on chromosome 7 is seen in about 40% of glioblastomas. It is mostly associated with the retention of the wild-type p53 gene, forming a distinct genetic subset (Lang et al., 1994a , Leenstra et al., 1994 Rasheed et al., 1994 Rasheed et al., , 1997 Tada et al., 1998) . While it is generally thought to be seen exclusively in grade IV tumors (Ekstrand et al., 1991; Lang et al., 1994a , von Deimling et al., 1992b , some authors have also reported it in lower-grade astrocytomas (Diedrich et al., 1995; Hurtt et al., 1992 
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PTEN is known to act as a dual speci city phosphatase, removing phosphate residues from tyrosines and serines (Myers et al., 1997) . Certain tyrosine phosphatases can inhibit the oncogenic activity of protein tyrosine kinase receptors by dephosphorylation (Brown-Shimer et al., 1992; Sorby and Ostman, 1996) . Therefore, it is worth investigating whether PTEN gene loss means a loss of the negative feedback mechanism of EGFR signaling.
Introduction of chromosome 10 can restore production of thrombospondin-1 (a potent inhibitor of angiogenesis) in glioma cells (Hsu et al., 1996) . This is interesting because endothelial proliferation is the hallmark that distinguishes glioblastoma from anaplastic astrocytoma (Barker et al., 1996), although it is unknown which chromosome 10 gene is responsible for this effect. More recently, it has been shown that the overexpression of PTEN can inhibit cell migration and the antisense suppression of PTEN expression can enhance cell migration (Tamura et al., 1998) . This is done partly by down-regulating integrin-mediated cell spreading and partly by abrogating focal adhesion, resulting from dephosphorylation of focal adhesion kinase (FAK). It is thus possible that PTEN gene loss confers invasiveness on the tumor cells, which is characteristically seen in glioblastomas.
p16 Loss, Ampli cation of CDK4, and RB Loss
Both p16 (INK4A/CDKN2A) and p15 (INK4B/CDKN2B) on chromosome 9p21 inhibit G 1 cyclin-dependent kinases CDK4 and CDK6 (Hannon and Beach, 1994; Kamb et al., 1994; Serrano et al., 1993) . They bind to the CDK and inhibit phosphorylation by CAK (CDK-activating kinase). Together with recently discovered p18 and p19 genes on chromosome 19p13, they constitute the INK4 family (Chan et al., 1995; Guan et al., 1994; Hirai et al., 1995) . Homozygous deletion of the p16 gene is found in about 40% of glioblastomas (Brown-Shimer et al., 1992; Myers et al., 1997) . Although there is disagreement over whether 0% (Izumoto et al., 1995; Moulton et al., 1995) or 20% (Schmidt et al., 1994; Uhrbom et al., 1997) of anaplastic astrocytomas display p16 loss, there is general consensus that the loss is not present in grade II astrocytomas, suggesting that p16 loss is associated with later stages of astrocytoma tumorigenesis/progression. On the other hand, homozygous deletions of the p15 gene occur only in 13% of glioblastomas (Izumoto et al., 1995) , suggesting that p16 is the main target of chromosome 9p21 deletion in glioblastomas. Most p16 inactivations in glioblastomas consist of homozygous deletions; point mutations are uncommon (Kyritsis et al., 1996) . In other types of human cancers, hypermethylation of the p16 promoter accounts for 20% of causes of p16 inactivation, but it is infrequent in gliomas (Schmidt et al., 1997) .
Quite interestingly, p16 loss is often associated with EGFR gene ampli cation Hegi et al., 1997) . In addition, glioblastomas without p16 loss often display CDK4 or CDK6 ampli cation and/or RB gene mutation (Costello et al., 1997; Ichimura et al., 1996; Schmidt et al., 1997; Sonoda et al., 1995; . Because CDK4/6 are the nal targets of EGFR signal transduction, ampli cation of the target genes may cooperate with the augmented EGFR signal. p16 introduction in glioma cells reduces cellular growth (Arap et al., 1995) . The functional signi cance of p16 deletion is not restricted to the in uence on cellular growth; inhibition of apoptosis is also implicated by lines of evidence that simultaneous expression of p16 and p53 induces apoptosis in tumor cells (Sandig et al., 1997) , that p16 introduction reverts immortalization in glioma cells (Uhrbom et al., 1997) , and that p16 can enhance the radiation sensitivity of glioma cells (Miyakoshi et al., 1997) . Since apoptosis by p16 overexpression in tumor cells requires the presence of the Rb protein (Costanzi-Strauss et al., 1998), it is likely that the above-mentioned decision of apoptosis by Rb-E2F is involved in this process, although this remains to be clari ed.
Three New Putative Tumor Suppressors Homologous to p53
Three new genes that are homologous to the p53 gene have been discovered successively in recent times (Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Trink et al., 1998) . According to their molecular weights, they are p73 (in two forms), p51, and p40, comprising four members of the p53 family.
p73 Gene
The p73 gene has recently been identi ed in the chromosome 1p36 region, which is frequently deleted in pediatric neuroblastomas (Jost et al., 1997; Kaghad et al., 1997) . Two alternative splice forms are known: p73a, which is composed of 636 amino acids, and p73b, which terminates at 499 amino acids due to a frameshifting splice-out of exon 13 (Kaghad et al., 1997) . The 420 amino acids on the N-terminal side make up the region homologous to p53, which contains a transactivation domain, a DNA-binding domain, and an oligomerization domain; functions of the remaining 610 amino acids for p73a and 80 amino acids for p73b are completely unknown (Fig. 2) . In contrast to the quite high homology of the DNA-binding domain, the transactivation domain of p73 shares relatively fewer sequences; p73 transcription is not activated by DNAdamaging agents such as actinomycin D and ionizing radiation. However, there is an MDM2 binding sequence in the domain, suggesting that p73 is also under negative control by MDM2, as is p53. In vitro p73 is able to perform many functions associated with the tumor suppressor function of p53; growth arrest, apoptosis, and transactivation. Although chromosome 1p36 loss has been described in a wide variety of human tumors including oligodendrogliomas and oligoastrocytomas (Maintz et al., 1997; Schiffer et al., 1995; Sure et al., 1997) , mutation in the p73 gene has not been found in several studies so far (Bello et al., 1994; Kraus et al., 1995; Mai et al., 1998; Nomoto et al., 1998; Sunahara et al., 1998; Takahashi et al., 1998) . Since losses of heterozygosity on 17p13.1 and 1p36 are not generally associated, p73 does not appear suf cient to compensate for loss of p53 function. 
p51 and p40 Genes
Two additional members of the p53 family-the p51 and the p40 genes-have been identi ed by different groups using degenerated primers and polymerase chain reaction (Osada et al., 1998; Trink et al., 1998) . In the DNA-binding domains, p51 and p40 are 60 and 55%, respectively, homologous to p53, and 85 and 87%, respectively, homologous to p73. As a whole, p51 and p40 appear more similar to p73 than to p53. Both p51 and p40 genes are located on the telomeric portion of chromosomal arm 3q. The p51 gene produces two alternative splice isoforms, p51A (50.9 kDa) and p51B (71.9 kDa), the former lacking exon 10 as p73b lacks exon 13 (Fig. 2) . p51B is expressed in various organs but not in brain; p51A is speci cally expressed in skeletal muscles. p40 is peculiar among the p53 family because it seems to lack an oligomerization domain (Fig. 2) . It is possible that p40 is identical to the p53 competing protein (p53CP), which was recently isolated by another group (Bian and Sun, 1997) . If it is, p40 might be a regulator of the p53 pathway by competing with p53 binding to DNA.
Concluding Remarks
Many attempts have failed to make a breakthrough in therapy for patients with malignant astrocytic tumors over the past two decades. Theories on which these past "innovative" therapies depended may have depended on a too-simple understanding of the characteristics of malignant gliomas. Recent molecular genetic studies have at least made it very clear that the disease is far more complex than previously thought. Methods are now available to stratify glioblastoma cases into at least two subsets, which are histologically indistinguishable but may respond differently to radio-and/or chemotherapies. In the near future, information on the status of several genes in a tumor will be essential to determine the most appropriate set of therapeutic agents and to evaluate the success of clinical trials. In this context, functional reconstitution of defective genes, by either gene therapy or chemical targeting of the related proteins, should be used in combination with conventional agents rather than alone. Efforts, therefore, should be continued to unveil genetic abnormalities and to relate them functionally to respond to therapeutic agents.
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